STAT Plus: The good, the bad, and the really, really ugly behind Sarepta’s drug approval
What does it all mean now that the Food and Drug Administration has issued a surprise decision to approve Sarepta Therapeutics’ Duchenne muscular dystrophy drug Vyondys 53, reversing its surprise decision to reject the drug in August?
Here are some thoughts and observations about the latest twist in the always twisty Sarepta story, including potential implications for Biogen and its controversial Alzheimer’s drug.
Continue to STAT Plus to read the full story…
